Copy For Citation
Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., ...More
FUTURE ONCOLOGY, vol.18, pp.323-331, 2022 (SCI-Expanded)
Article / Article
Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
adjuvant paclitaxel plus trastuzumab, APT trial, HER2-overexpressing breast cancer, node negative, real-life experience, PRIMARY THERAPY, JOINT ANALYSIS, FOLLOW-UP, CHEMOTHERAPY, WOMEN, SURVIVAL, OUTCOMES, TRIAL
Hacettepe University Affiliated:
Lay abstract In oncology practice, there have been some efforts to avoid the toxicity of combination chemotherapies and reduce the amount of treatment given in recent decades. These strategies have been studied especially for patients with a specific subtype of early-stage breast cancer. We present the results from patients treated in our centers and discuss them in relation to the literature.